Evidence map›Paper›PMID 32961930›Full record

ArticleInternational journal of molecular sciences2020

Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients.

Jorge Monserrat Sanz, Cristina Bohórquez, Ana Maria Gómez, Atusa Movasat, Ana Pérez, Lucía Ruíz, David Diaz, Ana Isabel Sánchez, Fernando Albarrán, Ignacio Sanz and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Review
  6. Research of Pathogenesis and Novel Therapeutics in Arthritis 2.0.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Jorge Monserrat SanzLaboratory of Immune System Diseases, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.ORCID 0000-0003-1775-4645
Cristina BohórquezImmune System Diseases-Rheumatology Service, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
Ana Maria GómezLaboratory of Immune System Diseases, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.ORCID 0000-0003-3981-5138
Atusa MovasatImmune System Diseases-Rheumatology Service, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
Ana PérezIRYCIS Unit, Instituto Ramón y Cajal de Investigación Sanitaria, 28034 Madrid, Spain.
Lucía RuízImmune System Diseases-Rheumatology Service, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
David DiazLaboratory of Immune System Diseases, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.
Ana Isabel SánchezImmune System Diseases-Rheumatology Service, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
Fernando AlbarránImmune System Diseases-Rheumatology Service, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
Ignacio SanzDivision of Immunology and Rheumatology, Department of Medicine, Emory University, Atlanta, GA 30322, USA.
Melchor Álvarez-MonLaboratory of Immune System Diseases, Department of Medicine, University Hospital "Príncipe de Asturias", University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.
Universidad de Alcalá · ESEmory University · US

Funding

Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI Ignacio E. Sanz · 2014 to 2026
$76.6M
METHADONE TREATMENT: A STUDY OF A COUNTY POLICY CHANGER01DA003804 · NIDA · SCIENTIFIC ANALYSIS CORPORATION · PI ROSENBAUM, MARSHA · 1985 to 1989
–
Instituto de Salud Carlos III (Plan Estatal de R+D+i 2013–2016) FIS-PI18/01726NIAID NIH HHS U19 AI110483Programa de Actividades de R+D de la Comunidad de Madrid en Biomedicina S2017/BMD-3804
6 · The paper itself

Abstract

CD4

Indexed as

AdultAntirheumatic AgentsArthritis, RheumatoidCD4-Positive T-LymphocytesCells, CulturedCytokinesFemaleFlow CytometryHumansInterferon-gammaInterleukin-17Interleukin-4MaleMethotrexateMiddle AgedPhosphorylationAntirheumatic AgentsCytokinesIL17A protein, humanIL4 protein, humanInterferon-gammaInterleukin-17Interleukin-4MethotrexateSTAT1 protein, humanSTAT1 Transcription FactorSTAT3 protein, humanSTAT3 Transcription FactorSTAT6 protein, humanSTAT6 Transcription FactorCD4+ T-lymphocytesIFNγ, IL-17Amethotrexate responsenaïve rheumatoid arthritisSTAT expression

Identifiers

PMID32961930
PMCPMC7555887
OpenAlexW3087667294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.